News -

Download the New Scientific Poster on iLite™ VEGF Assay Ready Cell line now!

The signaling protein Vascular Endothelial Growth Factor (VEGF) is a major contributor to angiogenesis in both health and disease. Since angiogenesis is required for tumour growth and metastasis, drugs targeting VEGF have been increasingly employed in a vast number of cancer therapies.

This new exciting iLite™ VEGF cell line that is intended to be used within the immune-oncology area has been genetically engineered to specifically detect VEGF activity, VEGF inhibitors and can be used to determine neutralizing antibodies against inhibitor drugs in human serum.

For more information, please see the iLite™ product page, and keep an eye out for more news regarding our iLite™ cell lines!

Click to download the poster "Quantification of Bevacizumab Activity and Anti-Bevacizumab Neutralizing Antibodies in a Cohort of Patients with Glioblastoma".

Related links

Topics

  • Diseases

Categories

  • ilite cell-based assays

Contacts

Trine Österbye

VP Biopharma Solutions iLite Cell-based Assays +46 40 53 76 47

Related media

Download the New Scientific Poster on iLite™ VEGF Assay Ready Cell line now!
  • Download the New Scientific Poster on iLite™ VEGF Assay Ready Cell line now!
  • License: All rights reserved
    The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
  • File format: .pdf
Not downloadable

Related content

Euro Diagnostica announces launch of a new Product Line - iLite® Assay Ready Cells for determination of ADCC activity

Euro Diagnostica AB announces the launch of the iLite ADCC Activity Assay product line and iLite anti-CD20 ADCC Activity Set. Using iLite ADCC Activity Assays, ADCC can be measured in a straight forward, sensitive and reproducible manner. Assay Ready Cells for determination of ADCC activity of antibodies targeting CD20 will be followed by Target cells for HER2, EGFR and membrane bound TNF-alpha.

Announcing the launch of iLite™ VEGF Assay Ready Cells

The launch of iLite™ VEGF Assay Ready Cells marks the first iLite™ reporter gene assay for use within the immuno-oncology area. The cells have been genetically engineered to specifically detect VEGF activity, and can be used to measure the potency of VEGF inhibitor drugs, as well as neutralizing antibodies against such drugs in human serum.

New research on cell-based reporter gene iLite™ assays

The 10th International Congress on Autoimmunity is taking place in Leipzig, Germany April 6-10. The event provides an opportunity to hear about the hot topics in autoimmunity and discuss the newest therapeutic techniques and diagnostic tools as well as the most up-to-date research. We are happy to announce that we will hold a presentation relating to the use of a cell-based reporter gene assay.

Euro Diagnostica is now launching a TLR4 responsive cell line, strengthening the iLite™ Assay Ready Cell portfolio within inflammation.

Toll-like receptor 4 (TLR4) plays a fundamental role in the activation of the innate immune response, which is why drug development of TLR4 antagonists is a hot topic for treatment of inflammatory diseases such as inflammatory bowel disease (IBD), rheumatoid arthritis and multiple sclerosis.